𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

✍ Scribed by Youngil Koh; Inho Kim; Sung-Soo Yoon; Byoung Kook Kim; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee; Eunkyung Park; Hyeoung-Joon Kim; Sang Kyun Sohn; Young Don Joo; Seok Jin Kim; Jooseop Chung; Ho-Jin Shin; Sung-Hyun Kim; Chul Soo Kim; Hong Suk Song; Min Kyoung Kim; Myung Soo Hyun; Jin Seok Ahn; Chul Won Jung; Seonyang Park; Korean Society of Hematology CML working party

Book ID
105989554
Publisher
Springer
Year
2010
Tongue
English
Weight
127 KB
Volume
89
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cytogenetic and molecular responses in c
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non